There were significant differences, however, in the levels of anti-Ap17-30 anti-Ap17-30 anti-Ap17-30the FOXE3p53-62-positive group (MAbn-whichey P <0.0001), and in the disease activity index, werehigherhinher (more acthee disease) in the FOXE3p53-62-positive group (Mann-Whitney P = 0.038).
As expected, the educational needs in both cohorts correlated with disease activity, which indicated that patients with more active disease were more interested in education.
Within both strata, we found that patients receiving biologics had significantly more active disease, and were more limited in activities of daily living (FFbH).
Patients receiving anti-TNF agents, rituximab, or other biologic drugs, had a significantly more active disease, and they were more limited in activities of daily living than patients treated with synthetic DMARDs only (table 1).
Disease activity was graded according to the 'Birmingham Vasculitis Activity Score' (BVAS, scores range from 0 to 63, with higher scores indicating more active disease) [ 18] and by investigators' assessments of disease activity as remission, ongoing active disease (treatment failure), or relapse.
Our data may reflect that in patients with more active disease, represented by more severe histopathology and higher levels of TTG IgA, there are more abnormalities in IELs subsets, mainly γδ IELs.
Compared to those without complications, they had worse performance status (PS) (57% vs 36% with PS ≥ 2, P < 0.001) and had more active disease (5% vs 43%, P < 0.001).
They found that a low level of vitamin D correlated with more lesions and a more active disease.
SLE patients with more active disease are likely to receive higher corticosteroid doses.
Thus, patients with poor response to IFNβ injections already had more active disease at treatment start.
